Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection

Mortality Clinical Trial

— BEYOND  

Official title:

Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection: The BEYOND Double-Blind Randomized Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05304715
• Other study ID #: BEYOND
• Secondary ID: 2021-005473-10
• Status: Completed
• Phase: Phase 2
• Start date: April 13, 2022
• Est. completion date: June 4, 2023

Study information

• Verified date: December 2023
• Source: Hellenic Institute for the Study of Sepsis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Previous data have shown that integrated information from single nucleotide polymorphisms (SNPs) of the host DNA, interleukin 8 (IL-8) and the enrichment of the stool microbiome can indicate the patients with infection by Clostridioides difficile (CDI) who are at risk for unfavorable outcome. This integrated information is forming the BEYOND score. The aim of the BEYOND randomized clinical trial (RCT) is to investigate if adjunctive bezlotoxumab treatment to the current standard-of-care may decrease the likelihood of unfavorable outcome for patients who score positive by the BEYOND score.

Description:

Clostridioides difficile infection (CDI) is an emerging infection with increased point-prevalence per year as reported both for the United States and for European countries. Current evidence suggests that CDI is a complex interaction between the host and the offending pathogen where physician intervention plays a pivotal role. Although originally conceived to be a hospital-acquired infection, it becomes more and more recognized that many cases are community-acquired. This underscores the significance of the host in the pathogenesis of CDI. CDI is traditionally considered to derive from the direct oral transmission from one host to the other in the hospital environment. However, a recent survey in three large hospitals in Wales analyzing the whole genome C.difficile isolated from 499 cases of diarrhea positive for glutamate dehydrogenase (GDH) revealed that the vast majority of isolates of C.difficile had different nucleotide sequences suggesting against the direct transmission from one patient to the other in the vast majority of cases. The complex interaction between the host and C.difficile ending to infection is modulated by environmental factors like antibiotic consumption, proton pump inhibitor intake and prolonged hospitalization. The main endpoint of all randomized clinical trials (RCTs) of new antimicrobials targeting C.difficile is sustained clinical response that is defined as the composite of the resolution of the infection at the end of treatment without any CDI relapse within the first 40 days. This endpoint is mainly targeting to demonstrate if newly developed agents are superior over the comparator vancomycin in the minimization of relapse risk. However, recent data outscore the lack of substantial merit of this endpoint as many cases of CDI bear an intrinsic danger of unfavorable outcome without this being incorporated in the RCT endpoints. More precisely, a substantial rate of patients dies after the end of oral treatment between days 12 and 40 probably as a result of emerging organ dysfunction in the field of CDI colitis. Recent epidemiological data coming from the United States challenge even more the traditional way of our thinking of CDI. More precisely, in a prospective survey of 30,326 patients it was shown that the risk of unfavorable outcome and death was greater among first-time infected patients than in relapsed cases. This survey reports that mortality from the first CDI case may be as high as 28%. These cases of CDI associated with an unfavorable outcome leading to surgery and hospitalization in an intensive care unit are associated with a tremendous cost mounting to $34,149 per case. Surprisingly when data of the two registration RCTs of fidaxomicin were combined reduced CDI mortality was shown over the comparator vancomycin treatment. This observation strengthens the belief that the substantial merit of new agents is not in preventing CDI relapse but in saving lives. The pivotal RCTs of fidaxomicin influenced the design of the MODIFY studies in a way that the inclusion criteria of these studies comprised not only cases of CDI infection of moderate severity but also patients with high chance of relapse. Half of the enrolled patient population was aged equal to or above 65 years and another quarter of enrolled patients had history of at least one episode of CDI. In these trials, patients with CDI receiving oral treatment with metronidazole, vancomycin or fidaxomicin were randomized to one single dose of adjunctive treatment with placebo or the monoclonal antibody targeting the toxin B of C.difficile bezlotoxumab, or the monoclonal antibody targeting the toxin A of C.difficile actoxumab or both antibodies. Results revealed that bezlotoxumab treatment reduced considerably the risk of relapse whereas the intake of actoxumab did not affect the clinical outcome of CDI. However, the efficacy of bezlotoxumab treatment on other variables of unfavorable outcome was not analyzed. One main argument against new treatments targeting C.difficile is the substantial cost. This argument is based on the fact that there are no tools that can discriminate between patients at high risk for unfavorable outcome that are in need of new treatments from patients at low risk from unfavorable outcome that will benefit from standard-of-care vancomycin treatment. In order to distinguish these patients, the investigators introduce a score which is called BEYOND. In this score, patients with CDI are at increased likelihood for unfavorable outcome if they meet any of the following: 1. Gene score for susceptibility to CDI more than 53. The score is provided by the following equation: (Carriage of C allele of rs12148744 x 27) - (carriage of C allele of rs714024 x 27) - (carriage of C allele of rs721059 x 29) + (carriage of T allele of rs4311028 x 33) - (carriage of A allele of rs62183547 x 25) + (carriage of C allele of rs1128266 x 12) - (carriage of T allele of rs4279595 x 17) + (carriage of G allele of rs175006 x 11) + (carriage of T allele of rs3859214 x 17) + (carriage of G allele of rs7222870 x 15) - (carriage of G allele of rs5086600 x 9) + (carriage of T allele of rs7240534 x 12) + (carriage of G allele of rs20911172 x 11) - (carriage of C allele of rs17680671 x 17) OR 2. Score provided by the following equation more than 9: [Hemoglobin <9.5 g/dl x 10] + [serum urea >64.5 mg/dl x 14] + [serum interleukin-8 >227 pg/ml x 19] - [carriage of G allele of rs2091172 x 17] OR 3. More than 3log10 of gammaproteobacteria or Enterobacteriaceae or Enterobacteriales in the stool

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: June 4, 2023
• Est. primary completion date: June 4, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age equal to or above18 years.

2. Both genders.

3. Written informed consent provided by the patient or by their legal representative in case of patients unable to consent.

4. In case of non-menopausal women, unwillingness to become pregnant during the study period. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study.

5. Diarrhea defined as at least 3 episodes of unformed stool in the past 24hours.

6. Positive stool for C.difficile. This is defined as any stool sample positive for the presence of glutamate dehydrogenase (GDH) and for the presence of toxin A and/or B.

7. Positive BEYOND score i.e. meeting any of the following:

Gene score for susceptibility to CDI more than 53. The score is provided by the following equation: (Carriage of C allele of rs12148744 x 27) - (carriage of C allele of rs714024 x 27) - (carriage of C allele of rs721059 x 29) + (carriage of T allele of rs4311028 x 33) - (carriage of A allele of rs62183547 x 25) + (carriage of C allele of rs1128266 x 12) - (carriage of T allele of rs4279595 x 17) + (carriage of G allele of rs175006 x 11) + (carriage of T allele of rs3859214 x 17) + (carriage of G allele of rs7222870 x 15) - (carriage of G allele of rs5086600 x 9) + (carriage of T allele of rs7240534 x 12) + (carriage of G allele of rs20911172 x 11) - (carriage of C allele of rs17680671 x 17) OR Score provided by the following equation more than 9: [Hemoglobin <9.5 g/dl x 10] + [serum urea >64.5 mg/dl x 14] + [serum interleukin-8 >227 pg/ml x 19] - [carriage of G allele of rs2091172 x 17] OR More than 3log10 of gammaproteobacteria or Enterobacteriaceae or Enterobacteriales in the stool

Exclusion Criteria:

• Age below 18 years
• Denial for written informed consent
• Known allergy to bezlotoxumab
• Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study

Related Conditions & MeSH terms

• Clostridioides Difficile Infection
• Clostridium Infections
• Communicable Diseases
• Infections
• Mortality
• Organ Dysfunction Syndrome
• Recurrence
• Stool Microbiome

Intervention

Drug:
• Bezlotoxumab
Single intravenous infusion of bezlotoxumab
• Normal saline 0.9% or 5% dextrose water
Single intravenous infusion - Placebo arm

Locations

Country	Name	City	State
Greece	2nd Department of Internal Medicine, University General Hospital of Alexandroupolis	Alexandroupoli
Greece	1st Department of Internal Medicine, THRIASIO General Hospital of Eleusis	Athens
Greece	1st University Department of Internal Medicine, LAIKO General Hospital of Athens,	Athens
Greece	1st University Department of Propaedeutic Surgery, IPPOKRATEION General Hospital	Athens
Greece	2nd Department of Internal Medicine, Thriasio General Hospital	Athens
Greece	4th Department of Internal Medicine, Attikon University Hospital	Athens
Greece	1st Department of Internal Medicine, General University Hospital of Ioannina	Ioannina
Greece	Department of Internal Medicine, Larissa University Hospital	Larisa
Greece	Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA	Patra
Greece	2nd Department of Internal Medicine, Tzanneion General Hospital	Piraeus
Greece	1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki	Thessaloniki

Sponsors (1)

Lead Sponsor	Collaborator
Hellenic Institute for the Study of Sepsis

Country where clinical trial is conducted

Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparison of bezlotoxumab over placebo on reducing the incidence of progression into organ dysfunction defined as any increase of the baseline total SOFA score by at least 2 points.	Progression into organ dysfunction is defined as any increase of the baseline total SOFA score by at least 2 points. Need for colectomy or admission in the Intensive Care Unit counts also as organ dysfunction.	40 days
Primary	Comparison of bezlotoxumab over placebo on reducing the incidence of relapse of Clostridioides difficile infection	Relapse is defined as the return of more than three unformed bowel movements in 24 hours with a positive stool toxin test necessitating retreatment	40 days
Primary	Comparison of bezlotoxumab over placebo on reducing the incidence of death	Death	40 days
Secondary	Comparison of bezlotoxumab over placebo regarding the time to first organ dysfunction	This is defined as the presentation of organ dysfunction in any of the enrolled patients of each group starting from the day of blind allocation until Day 40.	1-40 days
Secondary	Comparison of bezlotoxumab over placebo regarding the time to relapse of CDI	The relapse of CDI is under daily follow-up until Day 40. Relapse is defined as the return of more than three unformed bowel movements in 24 hours with a positive stool toxin test necessitating retreatment.	1-40 days
Secondary	Comparison of bezlotoxumab over placebo regarding survival time	Survival until Day 40 from study enrolment	1-40 days
Secondary	Comparison of bezlotoxumab over placebo regarding overall cost of hospitalization	This is calculated starting from the day of blind allocation until Day 40	1-40 days
Secondary	Validation of the BEYOND score	This is done by comparing the incidence of the primary endpoint between patients who have failed screening in the trial and patients who were enrolled in the trial and who were allocated to the placebo arm. Positive BEYOND score is expected to be associated with worse outcome.	1-40 days